Evaluation of the Epidoxorubicin–Formaldehyde Conjugate, Epidoxoform, in a Mouse Mammary Carcinoma Model

REFERENCES

• Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer Statistics 2001. CA Cancer J. Clin. 2001; 51: 15–36
   PubMed Web of Science ®Google Scholar
• Veronesi U., Marubini E., Del Vecchio M., Manzari A., Andreola S., Greco M., Luini A., Merson M., Saccozzi R., Rilke F. Local Recurrences and Distant Metastases After Conservative Breast Cancer Treatments: Partly Independent Events. J. Natl Cancer Inst. 1995; 87: 19–27
   PubMed Web of Science ®Google Scholar
• Silverstein M.J., Geirson E.D., Colburn W.J., Cope L.M., Furmanski, Senofsky G.M., Gamagami P., Waisman J.R. Can Intraductal Breast Carcinoma by Excised Completely by Local Excision?. Cancer 1994; 73: 2985–2989
   PubMed Web of Science ®Google Scholar
• Harris D.T. Adjuvant Systemic Therapy for Breast Cancer. Semin. Oncol. 1995; 22: 553–570
   PubMed Web of Science ®Google Scholar
• Bondonna G., Valagussa P., Zucali R., Salvadori B. Primary Chemotherapy in Surgically Resectable Breast Cancer. CA Cancer J. Clin. 1995; 45: 227–243
   PubMed Web of Science ®Google Scholar
• Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy: 133 Randomized Trials Involving 31,000 Recurrences and 24,000 Deaths Among 75,000 Women. Lancet 1992; 339: 1–15
   PubMed Web of Science ®Google Scholar
• Piccart M.J., Hortobagyi G.N. Conclusions: Future Strategies in the Treatment of Breast Cancer. Semin. Oncol. 1997; 4: S3-34–S3-40
   Google Scholar
• Abrams J.S., Moore T.D., Friedman M. New Chemotherapeutic Agents for Breast Cancer. Cancer 1994; 1164–1176
   PubMed Web of Science ®Google Scholar
• Sweatman T.W., Israel M. Anthracyclines. Cancer Therapeutics, Experimental and Clinical Agents, B.A. Teicher. Humana Press, Totowa, NJ 1997; 113–135
   Google Scholar
• Namer M. Anthracyclines in the Adjuvant Treatment of Breast Cancer. Drugs 1993; 45(suppl. 2)4–9
   PubMedGoogle Scholar
• Tomiak E., Piccart M., Mignolet F., Sahmoud T., Paridaens R., Nooy M., Beex L., Fentiman I.S., Muller A., van der Schueren E., Rubens R.D. Characterization of Complete Responders to Combination Chemotherapy for Advanced Breast Cancer: A Retrospective EORTC Breast Group Study. Eur. J. Cancer 1996; 32A: 1876–1887
   PubMed Web of Science ®Google Scholar
• Cullinane C., van Rosmalen A., Phillips D.R. Does Adriamycin Induce Interstrand Cross-Links in DNA?. Biochemistry 1994; 33: 4632–4638
   PubMed Web of Science ®Google Scholar
• Taatjes D.J., Gaudiano G., Resing K., et al. A Redox Pathway Leading to the Alkylation of DNA by the Anthracycline, Anti-Tumor Drugs, Adriamycin and Daunomycin. J. Med. Chem. 1997; 40: 1276–1286
   PubMed Web of Science ®Google Scholar
• Taatjes D.J., Gaudiano G., Koch T.H. Production of Formaldehyde and DNA-Adriamycin or -Daunomycin Adducts, Initiated Through Redox Chemistry of DTT/Iron, Xanthine Oxidase/NADH/Iron, or Glutathione/Iron. Chem. Res. Toxicol. 1997; 10: 953–961
   PubMed Web of Science ®Google Scholar
• Minotti G., Recalcati S., Mordente A., Liberi G., Calafiore A.M., Mancuso C., Preziosi P., Cairo G. The Secondary Alcohol Metabolite of Doxorubicin Irreversibly Inactivates Aconitase/Iron Regulatory Protein-1 in Cytosolic Fractions from Human Myocardium. FASEB J. 1998; 12: 541–552
   PubMed Web of Science ®Google Scholar
• Wang A.H.J., Gao Y.G., Liaw Y.C., Li Y.K. Formaldehyde Cross-Links Daunorubicin and DNA Efficiently: HPLC and X-Ray Diffraction Studies. Biochemistry 1991; 30: 3812–3815
   PubMed Web of Science ®Google Scholar
• Zeman S.M., Phillips D.R., Crothers D.M. Characterization of Covalent Adriamycin–DNA Adducts. Proc. Natl Acad. Sci. USA 1998; 95: 11561–11565
   PubMed Web of Science ®Google Scholar
• Podell E.R., Harrington D.J., Taatjes D.J., Koch T.H. Crystal Structure of Epidoxorubicin–Formaldehyde Virtual Crosslink of DNA and Evidence for Its Formation in Human Breast-Cancer Cells. Acta Crystallogr. 1999; D55: 1516–1523
   Google Scholar
• Taatjes D.J., Fenick D.J., Koch T.H. Nuclear Targeting and Nuclear Retention of Anthracycline–Formaldehyde Conjugates Implicates DNA Covalent Bonding in the Cytotoxic Mechanism of Anthracyclines. Chem. Res. Toxicol. 1999; 12: 588–596
   PubMed Web of Science ®Google Scholar
• Taatjes D.J., Koch T.H. Nuclear Targeting and Retention of Anthracycline Antitumor Drugs in Sensitive and Resistant Tumor Cells. Curr. Med. Chem. 2001; 8: 15–30
   PubMed Web of Science ®Google Scholar
• Olson R.D., Mushlin P.S. Doxorubicin Cardiotoxicity: Analyses of Prevailing Hypotheses. FASEB J. 1990; 4: 3076–3086
   PubMed Web of Science ®Google Scholar
• Doroshow J.H. Anthracyclines and Anthracenediones. Cancer Chemotherapy and Biotherapy, B.A. Chabner, D.L. Longo. 2nd Ed., Lippincott-Raven, Philadelphia 1996; 409–434
   Google Scholar
• Myers C. The Role of Iron in Doxorubicin-Induced Cardiotoxicity. Semin. Oncol. 1998; 25: 10–14
   PubMed Web of Science ®Google Scholar
• Fenick D.J., Taatjes D.J., Koch T.H. Doxoform and Daunoform: Anthracycline–Formaldehyde Conjugates Toxic to Resistant Tumor Cells. J. Med. Chem. 1997; 40: 2452–2461
   PubMed Web of Science ®Google Scholar
• Taatjes D.J., Fenick D.J., Koch T.H. Epidoxoform: A Hydrolytically More Stable Anthracycline–Formaldehyde Conjugate, Cytotoxic to Resistant Tumor Cells. J. Med. Chem. 1998; 41: 1306–1314
   PubMed Web of Science ®Google Scholar
• Taatjes D.J., Fenick D.J., Gaudiano G., Koch T.H. A Redox Pathway Leading to the Alkylation of Nucleic Acids by Doxorubicin and Related Anthracyclines: Application to the Design of Antitumor Drugs for Resistant Cancer. Curr. Pharm. Des. 1998; 4: 203–218
   PubMed Web of Science ®Google Scholar
• Ehrhart N., Withrow S.J., Dernell W.S., Ehrhart E.J., Hutchison J.M., Douple E.B., Brekke J.H., Straw R.C., Withrow S.J. Effects of a Controlled Release Cisplatin Delivery System Used After Resection of Mammary Carcinoma in Mice. Am. J. Vet. Res. 1999; 60: 1347–1351
   PubMed Web of Science ®Google Scholar
• Douple E.B., Richmond R.C. Radiosensitization of Hypoxic Tumor Cells by cis and trans Dichlorodiaminoplatinum. Int. J. Radiat. Oncol. Biol. Phys. 1979; 5: 1369–1372
   PubMed Web of Science ®Google Scholar
• Twentyman P.R., Kallman R.F., Brown J.M. The Effect of Time Between X-Irradiation and Chemotherapy on the Growth of Three Solid Mouse Tumors. Int. J. Radiat. Oncol. Biol. Phys. 1979; 5: 1365–1367
   PubMed Web of Science ®Google Scholar
• Morello, E.; Dernell, W.S.; Kuntz, C.A.; Nelson, A.; Manning, M.; Ehrhart, E.; Lafferty, M.; Withrow, S.J. Evaluation of Cisplatin in Combination with a Biologic Response Modifier in a Rodent Mammary Carcinoma Model, Proceedings of the 17th Annual Meeting of the Veterinary Cancer Society, Chicago, IL, 1997, p. 66
   Google Scholar
• Bregazzi V.S., Dernell W.S., Huber D.J., Schochet R., Lafferty M., Ogilvie G.K., Withrow S.J. Intracavity Slow Release of Paclitaxel Polymer in a Rodent Model of Mammary Carcinoma. J. Bioact. Compat. Polym. 2000; 15: 85–88
   Web of Science ®Google Scholar
• Mamounas E.P. Overview of National Surgical Adjuvant Breast Project Neoadjuvant Chemotherapy Studies. Semin. Oncol. 1998; 25: 31–35
   PubMed Web of Science ®Google Scholar
• Casazza A.M., Di Marco A., Bonadonna G., Bonfante V., Bertazzoli C., Bellini O., Pratesi G., Sala L., Ballerini L. Effects of Modifications in Position 4 of the Chromophore or in Position 4′ of the Aminosugar on the Antitumor Activity and Toxicity of Daunoribicin and Doxorubicin. Workshop on Anthracyclines. Academic Press, Norfolk, VA 1980; 4: 403–430
   Google Scholar
• Hortobagyi G.N., Frye D., Buzdar A.U., et al. Decreased Cardiac Toxicity of Doxorubicin Administered by Continuous Intravenous Infusion in Combination Chemotherapy for Metastatic Breast Carcinoma. Cancer 1989; 63: 37–45
   PubMed Web of Science ®Google Scholar
• Kubota T., Inoue S., Furukawa T., et al. Similarity of Serum–Tumor Pharmacokinetics of Antitumor Agents in Man and Nude Mice. Anticancer Res. 1993; 13: 1481–1484
   PubMed Web of Science ®Google Scholar
• Goldberg E.D., Karpova G.V., Kolmogorova L.A., Voronova O.L., Fomina T.I., Andreeva E.A. Myelotoxicity of Epirubicin. Antibiot. Khimioter. 1991; 36: 30–34
   Web of Science ®Google Scholar
• van der Vijgh W.J., Maessen P.A., Pinedo H.M. Comparative Metabolism and Pharmacokinetics of Doxorubicin and 4′-Epidoxorubicin in Plasma, Heart and Tumor of Tumor-Bearing Mice. Chemother. Pharmacol. 1990; 26: 9–12
   PubMed Web of Science ®Google Scholar
• Goldin A., Venditti J.M., Geran R. The Effectiveness of the Anthracycline Analog 4′-Epidoxorubicin in the Treatment of Experimental Tumors: A Review. Investig. New Drugs 1985; 3: 3–21
   PubMed Web of Science ®Google Scholar
• Myers C. The Role of Iron in Doxorubicin-Induced Cardiotoxicity. Semin. Oncol. 1998; 25: 10–14
   PubMed Web of Science ®Google Scholar
• Hryniuk W.M. Average Relative Dose Intensity and the Impact on Design of Clinical Trials. Semin Oncol. 1987; 14: 65–74
   PubMed Web of Science ®Google Scholar
• Norton L. Conceptual Basis for Advances in the Systemic Drug Therapy of Breast Cancer. Semin Oncol. 1997; 24: S11-2–S11-12
   Web of Science ®Google Scholar